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A B S T R A C T
Purpose: Data are accumulating to support the involvement of inﬂammatory mechanisms in the
pathogenesis and course of epilepsy.
Methods: The aim of this study was to examine seizure-induced changes in plasma concentrations of
interleukin-6 (IL-6), interleukin-1 receptor antagonist (IL-1Ra), and interleukin-1 beta (IL-1b) in 23
patients with epilepsy undergoing a video-electroencephalography (EEG) study. Patients were divided
into groups based on epilepsy type as follows: temporal lobe epilepsy (TLE) (n = 6), extra-temporal lobe
epilepsy (XLE) (n = 8) and idiopathic generalised epilepsy (IGE) (n = 9). Serum levels of IL-1b, IL-1Ra and
IL-6 were measured at baseline, immediately after the epileptic seizure, and at 3 h, 6 h, 12 h and 24 h
after the seizure.
Results: We demonstrated a signiﬁcant increase in plasma levels of IL-6 and IL-1Ra that peaked at 12 h
into the post-ictal period (p < 0.05). IL-1b levels did not differ from the baseline levels. We did not
observe any differences in post-ictal cytokine release patterns between the TLE, XLE and IGE groups.
Conclusion: The present study conﬁrms the ﬁndings that epileptic seizures induce the production of IL-6
and IL-1Ra.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Cytokines are a heterogeneous group of polypeptide com-
pounds that act principally as mediators of inﬂammatory signals in
peripheral tissues.1 In experimental models, an increased produc-
tion of inﬂammatory cytokines in association with epileptic
seizures has been demonstrated. The cytokines interleukin-1
(IL-1) and interleukin-6 (IL-6) receive much attention in this
regard.
The IL-1 cytokine family consists of IL-1 alpha, IL-1 beta (IL-1b)
and IL-1 receptor antagonist (IL-1Ra).2 Neurological conditions
such as stroke,3 trauma4 and Alzheimer’s disease5 are associated
with increased IL-1b production in the CNS. In low concentrations,
IL-1b is neuro-protective, but in pathological circumstances, high
levels of IL-1b lead to neurotoxic effects. Thus, it is associated with
seizure susceptibility and epileptogenesis.6 Increased mRNA levels
of IL-1b and IL-1Ra have been observed in experimentally induced
seizures.7–10 However, in most clinical studies, IL-1b levels
remained unchanged during the post-ictal period, and the reports
regarding seizure-induced changes in IL-1Ra levels have been
contradictory.11–13* Corresponding author. Tel.: +90 5304690368; fax: +90 2324570055.
E-mail address: fatmairem@yahoo.com (I.F. Uludag).
1059-1311/$ – see front matter  2013 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2013.03.004IL-6 is a pleiotropic cytokine with a spectrum of biologic actions
on various cell types and tissues.14 The expression of IL-6 is
increased in the setting of various neurological disorders such as
multiple sclerosis,15 Alzheimer’s disease,16 trauma17 and menin-
gitis.18 In transgenic mice that are over-expressing IL-6, neurologic
impairment is observed.19 Conversely, neuro-protective effects of
IL-6 are demonstrated in rat brain cultures.20,21 Increased IL-6
levels after both focal and secondarily generalised epileptic
seizures have been observed in clinical studies.13,22–24,16
The role of speciﬁc brain regions in controlling cytokine
responses and the signiﬁcance of seizure and epilepsy types for
the epilepsy-related immune responses are less well deﬁned.
In this study, we aimed to investigate changes in IL-6, IL-1b and
IL-1Ra levels triggered by epileptic seizures, as well as the time
interval and the relation of these changes with the type of epilepsy.
We recruited patients with epilepsy who were undergoing a video-
EEG study, which is a methodology that allowed us to accurately
diagnose and classify epileptic seizures and to assess their
temporal relationship with cytokine levels.
2. Methods
We studied consecutive patients who were admitted to the
video-EEG monitoring unit for pre-surgical epilepsy evaluation.
The Ethics Committee of the hospital approved the study, and allvier Ltd. All rights reserved.
Table 2
High and low baseline cytokine levels.
TLE XLE IGE Total
IL-6 > 1.5 pg/ml (%) 4/6 (66.7) 2/8 (25) 4/9 (44.4) 10 (43.5)
IL-1b>0.3 pg/ml (%) 5/6 (83.3) 6/8 (75) 8/9 (88.9) 19 (82.6)
IL-1Ra < 0.2 ng/ml (%) 5/6 (83.3) 8/8 (100) 8/9 (88.9) 21 (91.3)
I.F. Uludag et al. / Seizure 22 (2013) 457–461458the patients gave written informed consent. The inclusion criterion
was at least a 5-year history of epilepsy. Patients with seizures
within the last 24 h, trauma within the last 2 weeks, electrolyte
disturbances, history of alcohol or drug withdrawal, acute
neurological diseases, inﬂammatory, autoimmune, metabolic or
neoplastic diseases and patients using any other drugs other than
anti-epileptic medication were excluded. The study group con-
sisted of 18 men and 5 women. The mean age in the study group
was 27.74  8.91 years (range 15–46).
All patients underwent ﬁve days of video-EEG monitoring while
continuing anti-convulsant medications. Video-EEG monitoring
was performed using 21 scalp electrodes, which were placed
according to the International 10–20 System.
All seizures were characterised as single non-prolonged
seizures. The patients experienced no further seizures within
24 h after the index seizure.
TLE, XLE and IGE were diagnosed based on medical history,
electro-clinical ﬁndings (seizure semiology and EEG/video-EEG)
and neuro-imaging.12 A high-resolution 1.5 Tesla magnetic reso-
nance imaging (MRI) scan of the brain with a speciﬁc epilepsy
protocol was obtained to deﬁne the aetiology and was classiﬁed as
follows: normal, hippocampal sclerosis and other causes of
epilepsy such as chronic lesions of trauma, central nervous system
infection or stroke. Plasma samples were collected at 08.00 a.m. at
the beginning of the ﬁve-day recordings (baseline values) as soon
as possible after the ﬁrst seizure (0 h) and at 3, 6, 12 and 24 h after
the index seizure. The serum samples were immediately cen-
trifuged and frozen at 80 8C until further processing.
IL-6, IL-1Ra and IL-1b were measured by commercially
available ELISA (Enzyme Linked Immunosorbent Assay) kits
(Human IL-6 High Sensitivity ELISA, Bender MedSystems GmbH,
Austria; Human IL-1Ra Cytoscreen ELISA, Biosource, Belgium and
Human IL-1b Platinum ELISA, Bender MedSystems GmbH, Austria)
according to the manufacturers’ instructions.
We investigated signiﬁcant changes in serum cytokine levels
immediately after and at 3, 6, 12 and 24 h after the epileptic seizure
in the TLE, XLE and IGE groups.
Statistical calculations were carried out using Statistical
Package for the Social Sciences (SPSS) 13.00. The t-test was used
to compare baseline cytokine levels to the normal concentrations
of IL-1b, IL-1Ra and IL-6. Friedman analysis of variance (ANOVA)
with post- hoc comparisons (Wilcoxon matched pairs test) and the
Mann–Whitney U-test were used to compare cytokine levels atTable 1
Clinical characteristic of patients.
Epilepsy syndrome TLE 
n 6 
Female/male 1/5 
Age (mean  SD years) 31  10.51 (17–43) 
Epilepsy duration (mean  SD years) 17.83  9.75 (3–33) 
Seizure frequency (mean  SD seizure/month) 13  18.4 (2–50) 
Recorded index seizure type 4 CPS, 2 SGTCS 
Brain MRI (n, %)
Normal 5 (83.3) 
Hippocampal sclerosis 1 (16.7) 
Other causes – 
Side of epilepsy (n, %)
Right 2 (33.3) 
Left 0 
Unidentiﬁed 4 (66.7) 
Anti-epileptic drugs (n, %)
Without therapy 0 
Mono-therapy 0 
Bi-therapy 2 (33.3) 
Poly-therapy 4 (66.7) 
Refractory drug epilepsy (n, %) (>2 seizures/month
during last year)
4 (66.7) different time points. Correlations were calculated using Pearson
and Spearman correlation analyses. Findings were considered
statistically signiﬁcant at p values less than 0.05.
3. Results
The clinical characteristics of the patients are presented in
Table 1. The mean seizure frequency was 13  16.27 seizures per
month. The prominent seizure types were generalised tonic–clonic
seizures in IGE, secondary generalised tonic–clonic seizures in
patients with XLE and complex partial seizures in patients with
TLE. All patients in the IGE group had normal brain MRI. Hippocampal
sclerosis was observed in only one TLE patient. Chronic lesions of
trauma, encephalitis and brain infarction were observed in XLE
patients and were categorised as causes of epilepsy other than
hippocampal sclerosis (Table 1).
Baseline IL-1b levels were signiﬁcantly higher, and baseline IL-
1Ra levels were signiﬁcantly lower than in the normal population
(p < 0.01) (normal concentrations: 0.3 pg/ml for IL-1b and 0.2 ng/
ml for IL-1Ra).25,26 While the TLE group did not differ from the
normal population, then XLE and IGE groups showed lower IL-1Ra
(both p < 0.01) and higher IL-1b (p = 0.02 and p = 0.04 respective-
ly) levels than the normal population. Our patients’ baseline IL-6
levels were not different than those in the normal population
(normal concentration: 1.5 pg/ml)26 (Table 2).
Baseline cytokine levels were not correlated with the frequency
of seizures.
We observed a signiﬁcant increase in IL-6 and IL-1Ra in the 12-h
post-ictal period compared to the baseline measures. No signiﬁ-
cant post-ictal changes were observed for IL-1b (Tables 3–5, Figs. 1
and 2).
The IL-1b/IL-1Ra ratio decreased signiﬁcantly three hours after
the epileptic seizure (p = 0.03) (Table 6).
No signiﬁcant correlations of epilepsy syndrome with post-ictal
changes in the concentrations of IL-6, IL-1Ra, IL-1b or IL1b/IL-1Ra
were noted.XLE IGE Total
8 9 23
2/6 2/7 5/18
23.38  6.59 (16–35) 29.44  9.02 (15–46) 27.74  8.91 (15–46)
6.87  4.94 (1–13) 16.55  8.26 (8–37) 13.52  8.89 (1–37)
18.75  20.58 (3–60) 7.92  9.15 (0.3–30) 13  16.27 (0.3–60)
2 CPS, 6 SGTCS 9 GTCS 6 CPS, 8 SGTCS, 9 GTCS
5 (62.5) 9 (100) 19 (82.6)
– – 1(4.3)
3 (37.5) – 3 (13)
1 (12.5) 2 (22.2) 5 (21.7)
2 (25) 3 (33.3) 5 (21.7)
5 (62.5) 4 (44.4) 13 (56.5)
1 (12.5) 0 1 (4.3)
1 (12.5) 3 (33.3) 4 (17.4)
2 (25) 3 (33.3) 7 (30.4)
4 (50) 3 (33.3) 11 (47.8)
8 (100) 7 (77.8) 19 (82.6)
Table 3
Circulating concentrations of IL-6.
Epilepsy syndrome Baseline 0 h 3 h 6 h 12 h 24 h
TLE 4.44  5.29
(0.14–14.18)
1.04  0.86
(0.33–2.64)
2.3  3.5
(0.33–9.28)
5.23  6.63
(0.29–16.3)
10  8.78
(0.14–24.88)
3.24  4.8
(0.12–12.79)
XLE 3.05  6.12
(0.16–17.76)
1.13  0.88
(0.23–2.58)
1.87  2.29
(0.34–6.75)
1.55  2.15
(0.01–6.28)
7.51  11.14
(0.02–29.2)
3.28  4.94
(0.01–12.44)
IGE 1.33  1.29
(0.01–3.86)
4.3  9.54
(0.09–29.47)
1.95  2.68
(0.03–7.78)
12.31  20.88
(0.15–51.08)
5.37  6.26
(0.52–17.69)
8.91  11.92
(0.13–27.86)
Total 2.74  4.53
(0.01–17.76)
2.35  6
(0.09–29.47)
2.01  2.66
(0.03–9.28)
6.72  13.90
(0.01–51.08)
*7.32  8.65
(0.02–29.2)
5.47  8.52
(0.01–27.86)
Baseline: before the seizure; 0 h: immediate post-ictal state. Values in pg/ml, mean  SD.
* 12 h > baseline (p = 0.039).
Table 4
Circulating concentrations of IL-1Ra.
Baseline 0 h 3 h 6 h 12 h 24 h
TLE 99.12  104.32
(11.4–305.2)
124.8  129.78
(30.6–385.2)
127.38  106.81
(65–343.3)
174.95  177.19
(72.5–528.6)
172.98  119.32
(89.9–406)
154.83  119.56
(59.2–384.8)
XLE 78.18  21.64
(46.4–117.1)
80.23  15.5
(51.4–97)
89.26  23.68
(52.6–129.6)
78.54  13.63
(59.6–97)
98.81  39.28
(58.4–169.5)
76.09  14.45
(53–95.8)
IGE 170.52  227.17
(48.7–772.4)
204.43  263.75
(55.7–882.7)
190.5  233.47
(65.4–760.7)
186.8  247.73
(53–828.1)
191.73  264.39
(56.1–884.2)
119.18  68.25
(54.5–272.9)
Total 119.77  152.27
(11.4–772.4)
140.46  179.62
(30.6–882.7)
138.82  156.89
(52.6–760.7)
146.05  179.1
(53–828.1)
*154.52  175.88
(56.1–884.2)
113.49  77.44
(53–384.8)
Baseline: before the seizure; 0 h: Immediate post-ictal state. Values in pg/ml, mean  SD.
* 12 h > baseline (p = 0.019).
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levels showed more signiﬁcant increases in IL-6 and IL-1Ra
concentrations in the 12-h post-ictal period (p = 0.024 and 0.04 for
IL-6, respectively; p = 0.05 and p = 0.03 for IL-1Ra, respectively).
Baseline cytokine levels and the post-ictal changes in cytokine
levels were not inﬂuenced by the side of epilepsy, the frequency of
seizures, the aetiology of the seizures or the anti-epileptic drugs.
4. Discussion
Basal IL-6 levels may be increased in patients with chronic
epilepsy when compared with healthy controls.13,27,28 In some
studies, basal IL-6 has been reported to be more affected in patients
with TLE than in patients with XLE.27,28 In our patients, basal IL-6
levels did not differ from those in the normal population. A genetic
predisposition to higher production of IL-1b in TLE patients with
hippocampal sclerosis has been reported in Japanese patients.29
These results were not conﬁrmed in other case-control studies in
European and Chinese populations.30–32 TLE is the only epilepsy
syndrome with sufﬁcient data regarding the varied baseline
cytokine levels. In epileptic patients, we found higher baseline
levels of IL-1b and lower baseline levels of IL-1Ra than in the
normal population. These changes were especially signiﬁcant in
the XLE group. The activity of the IL-1 system depends on theTable 5
Circulating concentrations of IL-1b.
Baseline 0 h 3 h 
TLE 1.07  0.85
(0.08–2.24)
1.25  1.03
(0.08–2.78)
1.43  0.95
(0.35–2.51)
XLE 2.21  1.84
(0.08–5.21)
2.21  1.66
(0.62–5.75)
1.97  1.54
(0.08–3.86)
IGE 1.7  1.71
(0.07–5.48)
2.57  2.12
(0.08–7.1)
1.07  1.2
(0.08–3.86)
Total 1.71  1.58
(0.07–5.48)
2.1  1.75
(0.08–7.1)
1.48  1.28
(0.08–3.86)
Baseline: before the seizure; 0 h: Immediate post-ictal state. Values in pg/ml, mean  Sbalance between agonist/antagonist ligands, IL-1b and IL-1Ra.
Disequilibrium in the IL-1b/IL-1Ra ratio may increase the
inﬂammatory and neurotoxic potential of IL-1b and lead to brain
damage and epilepsy.33 One potential explanation for the high
levels of IL-1b and the low levels of IL-1Ra in our patients is a
cytokine gene polymorphism resulting in impaired inﬂammatory
responses and the development of epilepsy. The lack of signiﬁcant
variations in the baseline cytokine levels in the TLE group may be
due to the small number of cases (n = 6).
The main goal of the present study was to evaluate seizure-
induced changes in cytokine levels. We observed increased post-
ictal IL-6 and IL-1Ra levels that peaked at 12 h in both the TLE and
XLE groups. IL-1b levels remained unchanged in the TLE, XLE and
IGE groups. In experimental seizure models, exogenously applied
IL-1b worsens seizures, while the depression of IL-1b activity
suppresses them.10,34 The administration of exogenous IL-1Ra has
anti-convulsant effects.35 Experimental seizures are associated
with post-ictal increases of IL-1b in the CNS. In clinical studies, no
observable differences in IL-1b concentrations after seizures have
been observed.11–13,22 Peltola et al. compared plasma cytokine
levels of patients with recent (72 h) primarily generalised or partial
secondarily generalised tonic–clonic seizures to patients who
suffered a seizure more than 2 weeks previously. They attributed
the similar IL-1 levels to the short half-life of the cytokine.11 In6 h 12 h 24 h
1.07  1.09
(0.08–2.51)
1.12  1.31
(0.08–3.59)
1.03  0.44
(0.35–1.7)
2.07  1.51
(0.08–3.86)
2.81  2.27
(0.08–6.83)
2.38  1.75
(0.35–5.48)
3.11  4.26
(0.08–13.04)
1.79  1.58
(0.07–4.4)
9.07  19.94
(0.08–61.9)
2.22  2.88
(0.08–13.04)
1.97  1.84
(0.07–6.83)
4.64  12.61
(0.08–61.9)
D.
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Fig. 1. Mean and median IL-6 concentrations of the patients before and after the
index seizure.
Baseline: Before the seizure; 0 h: Immediate post-ictal state.
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Fig. 2. Mean and median IL-1Ra concentrations of the patients before and after the
index seizure.
I.F. Uludag et al. / Seizure 22 (2013) 457–4614602000, they analysed IL-1b and IL-Ra levels within 24 h of a seizure
in patients with newly developed tonic–clonic seizures, and they
compared these levels to those of controls. They showed a small
effect on IL-Ra concentrations, but even with this short sample
collection time, they could not show any changes in IL-1b levels.12
In a video-EEG study, Alapirtti et al. reported that post-ictal plasma
levels of IL-1Ra and IL-1b did not signiﬁcantly differ from baseline
levels in either the TLE or XLE groups.22 They suggested that the
augmentation in IL-1Ra, which is mainly induced by IL-1b, might
reﬂect the activation of the IL-1 system. The results of the study of
Lehtima¨ki et al. were similar and showed constant levels of IL-1b,
but there was an increase in IL-1Ra levels.13 The failure to show any
increase in IL-1b levels in these studies is thought to be caused by
the local production of the cytokine in very low quantities.36 Our
study results are in agreement with existing data on elevated IL-
1Ra and steady IL-1b serum concentrations after the epileptic
seizures. To better understand the status of the IL-1 system, we
analysed the changes in the IL-1b/IL-1Ra ratio. There was no
signiﬁcant increase in IL-b levels. IL-1Ra levels were increased at
12 h, but the IL-1b/IL-1Ra ratio had decreased at 3 h after the
epileptic seizure. We think that this result reﬂects the fast and
small increase of IL-1b that did not reach statistical signiﬁcance. In
this respect, the IL-1b/IL-1Ra ratio may provide more important
information than the IL-1Ra and IL-1b levels separately.
Experimental status epilepticus in rodents induced IL-6 levels
in the hippocampus.37,38 When exogenously applied, IL-6
increased the severity of chemically induced seizures in rats.30
In clinical studies, a rapid and transient post-ictal increase of IL-6
increase, which peaked at 12 h and remained for 24 h, has been
demonstrated.11,12,22,16 Our study results conﬁrm these clinicalTable 6
IL1b/IL-1Ra concentrations.
Baseline 0 h 3 h 
TLE 20.42  15.09
(0.26–42.59)
18.42  14.28
(0.21–34.25)
16.59  14.47
(3.21–33.38)
XLE 29.74  22.09
(0.68–60.91)
27.04  18.43
(6.81–61.56)
22.76  20.53
(0.81–60.79)
IGE 17.04  18.12
(0.45–58.42)
18.47  13.1
(1.26–34.39)
10.05  11.16**
(0.79–28.7)
Total 22.34  18.94
(0.26–60.91)
21.43  15.31
(0.21–61.56)
16.18  16.07*
(0.79–60.79)
Baseline: before the seizure; 0 h: Immediate post-ictal state. Values in mean  SD.
* 3 h > baseline (p = 0.03).
** 3 h > baseline (p = 0.01).trials with signiﬁcantly increased IL-6 levels at 12 h. The origin of
the increased cytokine levels in peripheral blood is discussed in the
literature. The rapidity of the changes in cytokine levels, the
correlation of the increase in cytokines with seizure severity and
more signiﬁcant changes in the CSF than in the plasma supports
intra-thecal synthesis.13,23 Lehtima¨ki et al. suggested that in-
creased serum levels of cytokines originate mainly from the
endothelial cells of the brain vessels and partially from the CSF
compartment via venous drainage.23 The up-regulation of IL-6 is
found to be correlated with the severity of the seizure.13,23 Alapirtti
et al. suggested that seizure-induced IL-6 production is more
signiﬁcant in patients with TLE than in patients with XLE. They
attributed this result to the effects of TLE on the hypothalamus-
pituitary axis resulting in different immunological responses.22
Different patterns of cytokine release may also exist between
different types of TLE; higher levels of IL-6 in patients with right-
sided seizure origin and lower levels of IL-6 in patients with
hippocampal sclerosis supports the neuroprotective role of IL-6
that was observed by Bauer et al.16
Induced IL-1Ra and IL-6 levels at 12 h were more signiﬁcant
among patients with high baseline IL-1b and low baseline IL-1Ra
concentrations. Baseline IL-1Ra levels were greater than 200 pg/ml
in only two of our patients (Table 2). Therefore, the relationship
between low baseline IL-1Ra concentrations and increased
cytokine levels at 12 h may be inconclusive, but we think that
the association of the high baseline IL-1b levels and the
inducibility at 12 h is remarkable.
Our study conﬁrms previous results showing post-ictal changes
in IL-1b, IL-1Ra and IL-6 levels.11–13,22 We documented cytokine
levels in the immediate post-ictal period and in the following 24 h,
so our results are not confounded by the short half-lives of the
cytokines. The timeline of the post-ictal increase on IL-6 and IL-1Ra
levels in our study were similar to previous reports22,16 (Figs. 1
and 2). Neuronal damage may induce cytokine release, and6 h 12 h 24 h
13.11  15.08
(0.46–31.85)
10.93  15.09
(0.2–39.93)
9.18  6.15
(1.92–19.59)
27.54  22.37
(1.05–59.02)
29.41  21.91
(0.93–61.47)
33.12  27.15
(4.09–84.31)
25.54  41.08
(0.31–131.72)
15.26  14.97
(0.31–38.9)
82.35  179.15
(0.29–557.16)
22.99  29.35
(0.31–131.72)
19.05  18.68
(0.2–61.47)
46.14  113.51
(0.29–557.16)
I.F. Uludag et al. / Seizure 22 (2013) 457–461 461seizure-related neuronal damage must be considered when
assessing post-ictal increases in interleukin levels. By excluding
cases of acute symptomatic seizures, we assume to have mostly
eliminated this factor. We aimed to evaluate the inﬂuence of the
different epilepsy syndromes on the post-ictal cytokine proﬁles. A
limitation of the study was the small number of cases. Further-
more, depth recordings were not available in our study, but we
carefully classiﬁed epilepsy types with clinical, radiological and
video-EEG ﬁndings. Nevertheless, we could not observe a more
signiﬁcant IL-6 increase in the TLE group as mentioned in some of
the recent studies.22
5. Conclusion
Both experimental and human data suggest a link between the
cytokine network and epileptic seizures. However, the mechanism
and clinical implications of these epilepsy-related immune
alterations need to be clariﬁed with a goal of developing potential
anti-epileptic treatment strategies.
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